[Personal experience with treatment of acute myeloid leukemia using the DAT combination].

Abstract

A combination of cytostatics--Rubomycin (Medexport), Alcysten (Spofa) and LANVIS (Wellcome) was used to treat 44 patients with the diagnosis AML. A total of 66% CR was achieved. The median duration of CR was 15 months and the median of survival of patients with CR was 25 months. 20% of the patients died in induction mostly from infectious complications. The authors assume that this combination with the use of the Czech preparation Alcysten and the Soviet preparation Rubomycin is suitable induction treatment in AML. Treatment, however, calls for perfect supporting therapy and therefore should by concentrated in selected departments.

• Authors: M Lukásová, M Sedlácková, V Chudomel
• Journal: Casopis lekaru ceskych (Cas Lek Cesk) Vol. 129 Issue 43 Pg. 1352-6 (Oct 26 1990) ISSN: 0008-7335 [Print] Czech Republic
• Vernacular Title: Nase zkusenosti s lécbou akutních myeloidních leukémií kombinací DAT.
• PMID: 2249232 (Publication Type: English Abstract, Journal Article)

Chemical References

• Tamoxifen
• Doxorubicin
• Mitolactol

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Doxorubicin (administration & dosage)
• Humans
• Leukemia, Myeloid (drug therapy)
• Middle Aged
• Mitolactol (administration & dosage)
• Tamoxifen (administration & dosage)